The Glycosylation of Immune Checkpoints and Their Applications in Oncology

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2022 Dec 23

PMID 36558902

Authors

Linlin Zheng

Qi Yang

Feifei Li

Min Zhu

Haochi Yang

Tian Tan

Binghuo Wu

Mingxin Liu

Chuan Xu

Jun Yin

Chenhui Cao

Affiliations

Soon will be listed here.

Abstract

Tumor therapies have entered the immunotherapy era. Immune checkpoint inhibitors have achieved tremendous success, with some patients achieving long-term tumor control. Tumors, on the other hand, can still accomplish immune evasion, which is aided by immune checkpoints. The majority of immune checkpoints are membrane glycoproteins, and abnormal tumor glycosylation may alter how the immune system perceives tumors, affecting the body's anti-tumor immunity. Furthermore, RNA can also be glycosylated, and GlycoRNA is important to the immune system. Glycosylation has emerged as a new hallmark of tumors, with glycosylation being considered a potential therapeutic approach. The glycosylation modification of immune checkpoints and the most recent advances in glycosylation-targeted immunotherapy are discussed in this review.

Citing Articles

Post-translational modifications in hepatocellular carcinoma: unlocking new frontiers in immunotherapy.

Piao Y, Zhai N, Zhang X, Zhao W, Li M Front Immunol. 2025; 16:1554372.

PMID: 40040703 PMC: 11876159. DOI: 10.3389/fimmu.2025.1554372.

The roles and mechanisms of coding and noncoding RNA variations in cancer.

Kim S, Na M, Yoon S, Shin E, Ha J, Jeon S Exp Mol Med. 2024; 56(9):1909-1920.

PMID: 39218979 PMC: 11447202. DOI: 10.1038/s12276-024-01307-x.

Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications.

Liu J, Xu X, Zhong H, Yu M, Abuduaini N, Zhang S Biomedicines. 2024; 12(7).

PMID: 39062019 PMC: 11274725. DOI: 10.3390/biomedicines12071446.

Can -GIcNAc Transferase (OGT) Complex Be Used as a Target for the Treatment of Hematological Malignancies?.

Zhuang S, Liu Z, Wu J, Yao Y, Li Z, Shen Y Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931332 PMC: 11206344. DOI: 10.3390/ph17060664.

Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.

Ren X, Lin S, Guan F, Kang H Int J Biol Sci. 2024; 20(7):2607-2621.

PMID: 38725856 PMC: 11077373. DOI: 10.7150/ijbs.93806.

References

Liu J, Wang G, Liu L, Wu R, Wu Y, Fang C . Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor. Sci Rep. 2019; 9(1):17830. PMC: 6882818. DOI: 10.1038/s41598-019-54231-w. View

Lafite P, Daniellou R . Rare and unusual glycosylation of peptides and proteins. Nat Prod Rep. 2012; 29(7):729-38. DOI: 10.1039/c2np20030a. View

Tan W, Jiang P, Zhang W, Hu Z, Lin S, Chen L . Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation. Mol Cell. 2021; 81(9):1890-1904.e7. DOI: 10.1016/j.molcel.2021.02.009. View

Okadome K, Baba Y, Nomoto D, Yagi T, Kalikawe R, Harada K . Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers. Br J Cancer. 2020; 122(10):1535-1543. PMC: 7217865. DOI: 10.1038/s41416-020-0811-0. View

Schjoldager K, Narimatsu Y, Joshi H, Clausen H . Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020; 21(12):729-749. DOI: 10.1038/s41580-020-00294-x. View

Brown M, Boles K, van der Merwe P, Kumar V, Mathew P, Barclay A . 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med. 1998; 188(11):2083-90. PMC: 2212392. DOI: 10.1084/jem.188.11.2083. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Forgione R, Di Carluccio C, Guzman-Caldentey J, Gaglione R, Battista F, Chiodo F . Unveiling Molecular Recognition of Sialoglycans by Human Siglec-10. iScience. 2020; 23(6):101231. PMC: 7306591. DOI: 10.1016/j.isci.2020.101231. View

Bitra A, Doukov T, Croft M, Zajonc D . Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier. J Biol Chem. 2018; 293(26):9958-9969. PMC: 6028974. DOI: 10.1074/jbc.RA118.003176. View

10.

Li C, Chong G, Zong G, Knorr D, Bournazos S, Aytenfisu A . Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fcγ Receptor Affinity and ADCC Activity. J Am Chem Soc. 2021; 143(20):7828-7838. PMC: 8283798. DOI: 10.1021/jacs.1c03174. View

11.

Zhang Y, Zhang C, Jiang H, Yang P, Lu H . Fishing the PTM proteome with chemical approaches using functional solid phases. Chem Soc Rev. 2015; 44(22):8260-87. DOI: 10.1039/c4cs00529e. View

12.

Sun R, Kim A, Murray A, Lim S . -Glycosylation Facilitates 4-1BB Membrane Localization by Avoiding Its Multimerization. Cells. 2022; 11(1). PMC: 8750214. DOI: 10.3390/cells11010162. View

13.

Nie H, Ju H, Fan J, Shi X, Cheng Y, Cang X . O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth. Nat Commun. 2020; 11(1):36. PMC: 6946671. DOI: 10.1038/s41467-019-13601-8. View

14.

Vinay D, Kwon B . 4-1BB signaling beyond T cells. Cell Mol Immunol. 2011; 8(4):281-4. PMC: 4002439. DOI: 10.1038/cmi.2010.82. View

15.

Freund P, Kerenyi M, Hager M, Wagner T, Wingelhofer B, Pham H . O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. Leukemia. 2017; 31(10):2132-2142. PMC: 5629373. DOI: 10.1038/leu.2017.4. View

16.

Oldenborg P, Zheleznyak A, Fang Y, Lagenaur C, Gresham H, Lindberg F . Role of CD47 as a marker of self on red blood cells. Science. 2000; 288(5473):2051-4. DOI: 10.1126/science.288.5473.2051. View

17.

MacLachlan B, Mason G, Greenshields-Watson A, Triebel F, Gallimore A, Cole D . Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. Eur J Immunol. 2020; 51(2):331-341. PMC: 8101287. DOI: 10.1002/eji.202048753. View

18.

Agresta L, Lehn M, Lampe K, Cantrell R, Hennies C, Szabo S . CD244 represents a new therapeutic target in head and neck squamous cell carcinoma. J Immunother Cancer. 2020; 8(1). PMC: 7174077. DOI: 10.1136/jitc-2019-000245. View

19.

Rinis N, Golden J, Marceau C, Carette J, Van Zandt M, Gilmore R . Editing N-Glycan Site Occupancy with Small-Molecule Oligosaccharyltransferase Inhibitors. Cell Chem Biol. 2018; 25(10):1231-1241.e4. PMC: 6337728. DOI: 10.1016/j.chembiol.2018.07.005. View

20.

Andresen L, Skovbakke S, Persson G, Hagemann-Jensen M, Hansen K, Jensen H . 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation. J Immunol. 2012; 188(4):1847-55. DOI: 10.4049/jimmunol.1004085. View